Precigen (NASDAQ: PGEN)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.130 | -0.100 | 0.0300 | ||||
REV | 23.270M | 32.021M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Precigen (NASDAQ: PGEN) through any online brokerage.
Other companies in Precigen’s space includes: Humacyte (NASDAQ:HUMA), bluebird bio (NASDAQ:BLUE), Burning Rock Biotech (NASDAQ:BNR), Adaptimmune Therapeutics (NASDAQ:ADAP) and Mesoblast (NASDAQ:MESO).
The latest price target for Precigen (NASDAQ: PGEN) was reported by Stifel on Thursday, February 25, 2021. The analyst firm set a price target for 13.00 expecting PGEN to rise to within 12 months (a possible 821.99% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Precigen (NASDAQ: PGEN) is $1.41 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Precigen.
Precigen’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Precigen.
Precigen is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.